Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Total Non-Current Liabilities (2016 - 2024)

Crescent Biopharma (CBIO) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $4.3 million as the latest value for Q3 2024.

  • For Q3 2024, Total Non-Current Liabilities fell 35.04% year-over-year to $4.3 million; the TTM value through Sep 2024 reached $4.3 million, down 35.04%, while the annual FY2023 figure was $6.9 million, 22.28% down from the prior year.
  • Total Non-Current Liabilities hit $4.3 million in Q3 2024 for Crescent Biopharma, down from $4.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $14.6 million in Q4 2020 and bottomed at $4.3 million in Q3 2024.
  • Average Total Non-Current Liabilities over 5 years is $9.5 million, with a median of $9.3 million recorded in 2022.
  • Year-over-year, Total Non-Current Liabilities rose 7.28% in 2022 and then plummeted 49.83% in 2023.
  • Crescent Biopharma's Total Non-Current Liabilities stood at $14.6 million in 2020, then fell by 12.8% to $12.7 million in 2021, then crashed by 30.31% to $8.9 million in 2022, then dropped by 22.28% to $6.9 million in 2023, then plummeted by 37.38% to $4.3 million in 2024.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $4.3 million, $4.4 million, and $5.3 million for Q3 2024, Q2 2024, and Q1 2024 respectively.